The "Diabetic Retinopathy - Pipeline Insight, 2026" report highlights growth opportunities with over 50 companies and 55 drugs in development across varied stages. Key prospects include advancing anti-VEGF therapies like Tarcocimab and novel approaches such as THN391 targeting fibrin-mediated inflammation, with a focus on improving treatment efficacy and outcomes. The "Diabetic Retinopathy - Pipeline Insight, 2026" report highlights growth opportunities with over 50 companies and 55 drugs in dev